
    
      The study will have three groups: Rotarix 3-Dose Group, Rotarix 2-Dose Group and Placebo
      Group. Three-dose immunisation will be administered in healthy infants at approximately 6,
      10, and 14 weeks of age. Routine EPI vaccinations will be administered concomitantly with the
      study vaccines. This study will also evaluate immunogenicity and safety relative to the
      placebo.
    
  